(Q37298994)

19 August 2017

1 reference

title

Treatment of the elderly colorectal cancer patient: SIOG expert recommendations (English)

1 reference

19 August 2017

1 reference

1 reference

1 reference

4

B Glimelius

1 reference

19 August 2017

D Papamichael

1

1 reference

19 August 2017

R Audisio

2

1 reference

19 August 2017

J-C Horiot

3

1 reference

19 August 2017

J Sastre

5

1 reference

19 August 2017

E Mitry

6

1 reference

19 August 2017

E Van Cutsem

7

1 reference

19 August 2017

M Gosney

8

1 reference

19 August 2017

C-H Köhne

9

1 reference

19 August 2017

M Aapro

10

1 reference

19 August 2017

SIOG

11

1 reference

19 August 2017

publication date

15 October 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

20

1 reference

19 August 2017

issue

1

1 reference

19 August 2017

page(s)

5-16

1 reference

Never too old? Age should not be a barrier to enrollment in cancer clinical trials

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

The illness trajectory of elderly cancer patients across cultures: SIOG position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Age and adjuvant chemotherapy use after surgery for stage III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Colonic screening and surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Faecal occult blood testing in the secondary prevention of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Randomised controlled trial of faecal-occult-blood screening for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Screening for colorectal cancer reduces emergency admissions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Quality in the technical performance of screening flexible sigmoidoscopy: recommendations of an international multi-society task group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Colonoscopy in the very elderly is safe and worthwhile

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Meta-analysis: computed tomographic colonography

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Three-dimensional endoluminal CT colonography (virtual colonoscopy): comparison of three commercially available systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Clinical assessment of elderly people with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

COSTS OF FLEXIBLE SIGMOIDOSCOPY SCREENING FOR COLORECTAL CANCER IN THE UNITED KINGDOM

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Faecal occult blood screening for colorectal cancer: is it cost-effective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Colorectal cancer, screening and survival: the influence of socio-economic deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Comorbidity, disability, and geriatric syndromes in elderly cancer patients receiving home health care

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Postoperative mortality after cancer surgery in octogenarians and nonagenarians: results from a series of 5,390 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Elective surgery for gastrointestinal tumours in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Outcomes after major hepatectomy in elderly patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Towards a pan-European consensus on the treatment of patients with colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Optimising surgical management of elderly cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Sphincter preservation in rectal cancer. Endocavitary radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Total mesorectal excision (TME) with or without preoperative radiotherapy in the treatment of primary rectal cancer. Prospective randomised trial with standard operative and histopathological techniques. Dutch ColoRectal Cancer Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Preoperative radiotherapy improves survival for patients undergoing total mesorectal excision for stage T3 low rectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Are survival rates different for young and older patients with rectal cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Short-course preoperative radiotherapy with delayed surgery in rectal cancer - a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Preoperative sequential short-term radiotherapy plus chemotherapy can induce complete remission in T3N2 rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Adjuvant therapy in the elderly: making the right decision

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

Managing older patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN532

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDN532

1 reference

19 August 2017

1 reference